Cargando…
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
CYD-TDV is the first licensed dengue vaccine for individuals 9–45 (or 60) years of age. Using 12% of the subjects enroled in phase-2b and phase-3 trials for which baseline serostatus was measured, the vaccine-induced protection against virologically confirmed dengue during active surveillance (0–25...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128884/ https://www.ncbi.nlm.nih.gov/pubmed/30194294 http://dx.doi.org/10.1038/s41467-018-06006-6 |